UNSPSC 51332871: Promazine phosphate

This classification denotes a phenothiazine and antipsychotic agent C17H20N2S.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M4011G9T8I, chemically known as 10h-phenothiazine-10-propanamine, n,n-dimethyl-, phosphate, but more generally known as promazine phosphate, which bears US NIH Compound Identifier 200325. European Medicines Agency schedules Promazine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04068MIG.

Most nations, for tariff and trade purposes, schedule promazine phosphate under HS 29343090 and SITC 51578. As of Q4 2014, PROMAZINE PHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCCN1C2CCCCC2SC3C1CCCC3.OP(=O)(O)O.

UNSPSC 51332871 Promazine phosphate is a Commodity code that captures pharmaceutical procurement by state and local health agencies, though recent state and local opportunities tagged to this code diverge significantly from promazine phosphate specifically. The code appears in active use for broader pharmaceutical sourcing — state health and human services departments, county health systems, and cooperative purchasing alliances are soliciting generic multi-source drugs, naloxone, and OTC products through this taxonomy. Work being solicited includes manufacturer supply of FDA-compliant generic pharmaceuticals with specific National Drug Codes (NDCs), emergency response medications like naloxone with documented chain-of-custody, and direct-to-manufacturer prescription programs designed to bypass traditional pharmacy benefit managers and group purchasing organizations. Issuing bodies span state departments of health and human services, county community health systems, and multi-state cooperative purchasing alliances administering contracts on behalf of multiple member jurisdictions and participating states.

Recent activity clusters in Texas, Florida, and Minnesota. The Texas Health and Human Services Commission posted a Request for Information (RFI) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring how vendors can establish direct contracts with state agencies and self-insured health plans without traditional PBM or GPO intermediaries. Seminole County, Florida issued an Invitation for Bid (IFB 60459723LAS) in June 2026 with a July 26, 2023, response deadline for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the county community health building and E-Verify compliance required. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted a Request for Proposal (S1070000015802) due March 26, 2026, to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, requiring NDC-specific product information, cGMP certification, Drug Supply Chain Security Act compliance, and relationships with authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson).